Company intelligence / Profile preview
Novavax
Gaithersburg, Maryland, USAnovavax.com ↗
- Ownership
- Public · NVAX
- Employees
- ~1570
- Development stage
- Commercial
01
Overview
Novavax’s original COVID vaccine demonstrated ~90% efficacy in Phase 3 trials. The company has since developed updated versions targeting new variants such as Omicron XBB.1.5 and JN.1; the latest candidate NVX-CoV2601 showed superior immune responses compared to earlier versions in Phase 2/3 studies[8][10]. The FDA authorized an updated Novavax vaccine targeting JN.1 in August 2024[10].
- Therapeutic areas
- Infectious Diseases
- Modalities
- Protein subunit vaccinesrecombinant nanoparticle vaccinesadjuvanted vaccines
- Industry
- Biotech
02
Drug pipeline
63 assets62 more assets in the full pipeline.
03
Partnerships
Sanofi (global commercialization partnership announced in early/mid–2024)[6]Emergent BioSolutions (manufacturing collaboration)[6]Coalition for Epidemic Preparedness Innovations—CEPI (funding/development support)[2][6]
04
Financials
- Market cap
- $1.6B
- Total revenue
- $1.1B
- Enterprise value
- $1.3B
Beyond the preview
Go deeper on Novavax.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novavax.